Muhammad Osman1, Kevin Lee2, Karen Du Preez1, Rory Dunbar1, Anneke C Hesseling1, James A Seddon1,3. 1. Desmond Tutu Tuberculosis Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg. 2. City of Cape Town Health Directorate, South Africa. 3. Centre for International Child Health, Imperial College London, United Kingdom.
Abstract
BACKGROUND: Tuberculosis (TB) remains a leading cause of death in children globally. It is recognized that human immunodeficiency virus (HIV) infection increases the risk of developing TB, but our understanding of the impact of HIV on risk of mortality for children treated for TB is limited. We aimed to identify predictors of mortality in children treated for drug-susceptible TB. METHODS: A retrospective analysis of all children (<15 years of age) routinely treated between 2005 and 2012 for drug-susceptible TB in Cape Town was conducted using the programmatic electronic TB treatment database. Survival analysis using Cox regression was used to estimate hazard ratios for death. Logistic regression was used to estimate the odds of unfavorable outcomes. RESULTS: Of 29519 children treated for and notified with TB over the study period, <1% died during TB treatment and 89.5% were cured or completed treatment. The proportion of children with known HIV status increased from 13% in 2005 to 95% in 2012. Children aged <2 years had an increased hazard of death (adjusted hazard ratio [aHR], 3.13; 95% confidence interval [CI], 1.78-5.52) and greater odds of unfavorable outcome (adjusted odds ratio [aOR], 1.44; 95% CI, 1.24-1.66) compared with children aged 10-14 years. HIV-infected children had increased mortality compared to HIV-negative children (aHR, 6.85; 95% CI, 4.60-10.19) and increased odds of unfavorable outcome (aOR, 2.01; 95% CI, 1.81-2.23). Later year of TB treatment was a protective predictor for both mortality and unfavorable outcome. CONCLUSIONS: We demonstrate a dramatic improvement in HIV testing in children with TB over time and excellent overall treatment outcomes. HIV infection and young age were associated with increased risk of death and unfavorable outcome.
BACKGROUND: Tuberculosis (TB) remains a leading cause of death in children globally. It is recognized that human immunodeficiency virus (HIV) infection increases the risk of developing TB, but our understanding of the impact of HIV on risk of mortality for children treated for TB is limited. We aimed to identify predictors of mortality in children treated for drug-susceptible TB. METHODS: A retrospective analysis of all children (<15 years of age) routinely treated between 2005 and 2012 for drug-susceptible TB in Cape Town was conducted using the programmatic electronic TB treatment database. Survival analysis using Cox regression was used to estimate hazard ratios for death. Logistic regression was used to estimate the odds of unfavorable outcomes. RESULTS: Of 29519 children treated for and notified with TB over the study period, <1% died during TB treatment and 89.5% were cured or completed treatment. The proportion of children with known HIV status increased from 13% in 2005 to 95% in 2012. Children aged <2 years had an increased hazard of death (adjusted hazard ratio [aHR], 3.13; 95% confidence interval [CI], 1.78-5.52) and greater odds of unfavorable outcome (adjusted odds ratio [aOR], 1.44; 95% CI, 1.24-1.66) compared with children aged 10-14 years. HIV-infected children had increased mortality compared to HIV-negative children (aHR, 6.85; 95% CI, 4.60-10.19) and increased odds of unfavorable outcome (aOR, 2.01; 95% CI, 1.81-2.23). Later year of TB treatment was a protective predictor for both mortality and unfavorable outcome. CONCLUSIONS: We demonstrate a dramatic improvement in HIV testing in children with TB over time and excellent overall treatment outcomes. HIV infection and young age were associated with increased risk of death and unfavorable outcome.
Authors: S Ade; A D Harries; A Trébucq; S G Hinderaker; G Ade; G Agodokpessi; D Affolabi; S Koumakpaï; S Anagonou; M Gninafon Journal: Public Health Action Date: 2013-03-21
Authors: Y D Mukadi; S Z Wiktor; I M Coulibaly; D Coulibaly; A Mbengue; A M Folquet; A Ackah; M Sassan-Morokro; D Bonnard; C Maurice; C Nolan; J K Kreiss; A E Greenberg Journal: AIDS Date: 1997-07-15 Impact factor: 4.177
Authors: Bongani M Mayosi; Joy E Lawn; Ashley van Niekerk; Debbie Bradshaw; Salim S Abdool Karim; Hoosen M Coovadia Journal: Lancet Date: 2012-11-30 Impact factor: 79.321
Authors: Silvia S Chiang; Faiz Ahmad Khan; Meredith B Milstein; Arielle W Tolman; Andrea Benedetti; Jeffrey R Starke; Mercedes C Becerra Journal: Lancet Infect Dis Date: 2014-08-06 Impact factor: 25.071
Authors: Meg Osler; Katherine Hilderbrand; Claudine Hennessey; Juanita Arendse; Eric Goemaere; Nathan Ford; Andrew Boulle Journal: J Int AIDS Soc Date: 2014-04-28 Impact factor: 5.396
Authors: J A Seddon; H E Jenkins; L Liu; T Cohen; R E Black; T Vos; M C Becerra; S M Graham; C Sismanidis; P J Dodd Journal: Int J Tuberc Lung Dis Date: 2015-12 Impact factor: 2.373
Authors: A Roy; M Eisenhut; R J Harris; L C Rodrigues; S Sridhar; S Habermann; L Snell; P Mangtani; I Adetifa; A Lalvani; I Abubakar Journal: BMJ Date: 2014-08-05
Authors: Leonardo Martinez; Ye Shen; Andreas Handel; Srijita Chakraburty; Catherine M Stein; LaShaunda L Malone; W Henry Boom; Frederick D Quinn; Moses L Joloba; Christopher C Whalen; Sarah Zalwango Journal: Lancet Respir Med Date: 2017-12-19 Impact factor: 30.700
Authors: Anthony Enimil; Sampson Antwi; Hongmei Yang; Albert Dompreh; Wael A Alghamdi; Fizza S Gillani; Antoinette Orstin; Dennis Bosomtwe; Theresa Opoku; Jennifer Norman; Lubbe Wiesner; Taimour Langaee; Charles A Peloquin; Michael H Court; David J Greenblatt; Awewura Kwara Journal: Antimicrob Agents Chemother Date: 2019-09-23 Impact factor: 5.191
Authors: Karen du Preez; H Simon Schaaf; Rory Dunbar; Elisabetta Walters; Alvera Swartz; Regan Solomons; Anneke C Hesseling Journal: BMC Public Health Date: 2018-03-23 Impact factor: 3.295
Authors: Amita Gupta; Michael D Hughes; Anthony J Garcia-Prats; Katherine McIntire; Anneke C Hesseling Journal: PLoS Med Date: 2019-08-15 Impact factor: 11.069
Authors: Muhammad Osman; Karen du Preez; James A Seddon; Mareli M Claassens; Rory Dunbar; Sicelo S Dlamini; Alex Welte; Pren Naidoo; Anneke C Hesseling Journal: Pediatrics Date: 2021-03-10 Impact factor: 7.124
Authors: Anna M Mandalakas; Alexander W Kay; Jason M Bacha; Tara Devezin; Rachel Golin; Katherine R Simon; Dilsher Dhillon; Sandile Dlamini; Andrew DiNardo; Mogo Matshaba; Jill Sanders; Lineo Thahane; Pauline M Amuge; Saeed Ahmed; Moorine P Sekadde; Neway G Fida; Bhekumusa Lukhele; Nodumo Chidah; David Damba; Joseph Mhango; Moses Chodota; Makhorong Matsoso; Angelina Kayabu; Richard S Wanless; Gordon E Schutze Journal: Emerg Infect Dis Date: 2020-12 Impact factor: 6.883